Zealand Pharma A/S
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -1.03 | -100% |
| P/S |
|
15.98 | 33.76 | -52.66% |
|
|
| P/BV |
|
6.79 | 4.82 | 40.85% |
|
|
| P/FCF |
|
-0.5506 | 61 | -100.9% |
|
|
| Ev/Ebitda |
|
-0.65 | -22.15 | -97.07% |
|
|
| Ev/S |
|
2.01 | 22.56 | -91.11% |
|
|
| Ev/FCF |
|
-0.5126 | 68.78 | -100.75% |
|
|
| E/P |
|
-1.47 | 0.0178 | -8370.65% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-336.13 | 4.98 | -6853.75% | -79.86 | +320.92% |
| ROE |
|
-80.68 | 9.61 | -939.4% |
|
|
| ROA |
|
-31.66 | 0.3443 | -9296.55% |
|
|
| ROIC |
|
-59.96 | 7.63 | -885.4% |
|
|
| ROS |
|
-316.99 | -25.17 | 1159.4% |
|
|
| ROCE |
|
0 | 15.35 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.801 | -3.68 | -78.21% | -1.11 | -27.67% |
| Nеt Debt/Ebitda |
|
0 | -3.44 | -100% |
|
|
| Debt/Ratio |
|
0 | 0.1985 | -100% |
|
|
| Debt/Equity |
|
0 | 1.51 | -100% |
|
|
| Debt/Net Income |
|
-0.8257 | 10.32 | -108% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5468 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.1053 | -100% | ||
| DSI |
|
0 | 0.2174 | -100% |
|
|
| Average dividend growth |
|
0 | 0.0635 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.494 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5468 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
109.31 | -56.89 | -292.14% | ||
| Growth impulse Ebitda in 5 years |
|
286.7 | -54.68 | -624.32% | ||
| Growth impulse Net Income in 5 years |
|
273.95 | -58.33 | -569.66% | ||
| Growth impulse FCF in 5 years |
|
331.55 | -49.48 | -770.07% | ||
| Growth impulse EPS in 5 years |
|
-164.82 | -32.41 | 408.55% |
IP Score
4.4/10
